S ystemic lupus erythematosus is an autoimmune disorder often characterized by the development of glomerulonephritis. 1 Renal involvement remains the strongest predictor of morbidity and mortality among patients with lupus, 1 and despite improvements in the management of lupus, the incidence of end-stage renal disease has not declined. 2 Management of lupus nephritis consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse, progression to end-stage renal disease, and death. 3 However, the options for longterm therapy remain controversial. Treatment options include glucocorticoids and the immunosuppressive agents cyclophosphamide, azathioprine, and mycophenolate mofetil. These drugs have considerable toxicity and are not effective in all patients. 4, 5 There has been mounting interest in the use of mycophenolate mofetil as induction therapy, maintenance therapy, or both for patients with lupus nephritis. [6] [7] [8] [9] [10] [11] [12] The Aspreva Lupus Management Study (ALMS), which examined the efficacy and safety of induction therapy with mycophenolate mofetil as compared with intravenous cyclophosphamide (plus standardized tapering of glucocorticoid therapy) in patients with active lupus nephritis (renal-biopsy active class III, IV, or V [13] [14] [15] [16] [according to the International Society of Nephrology and Renal Pathology Society 2003 Classification of Lupus Nephritis 17 ]), showed no significant difference between the two drugs. 13 (For a description of the classes of renal biopsy used in this study, see the protocol, available with the full text of this article at NEJM.org.) Here we report the results of a 36-month study of maintenance therapy with either mycophenolate mofetil or azathioprine in patients who had a specified response to treatment during the ALMS induction study.
Me thods

Study Design and Oversight
We conducted a prospective, randomized, doubleblind, double-dummy, phase 3 study comparing mycophenolate mofetil (CellCept, Roche) with azathioprine (Imuran, GlaxoSmithKline) for the maintenance of remission in patients with lupus nephritis. Results of the induction study and detailed descriptions of methods for both phases have been reported previously. 13, 18 The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice principles. The institutional review boards at the participating centers approved the protocol, and all patients or their representatives provided written informed consent. The study was conducted in accordance with the protocol and all amendments.
The study was funded by Vifor Pharma (formerly Aspreva Pharmaceuticals) as part of the Roche-Aspreva rare diseases collaboration. All the investigators have confidentiality agreements with Vifor Pharma. Seven of the academic authors and two authors who are employees of the sponsor conceived of and designed the study, seven of the academic authors collected the data, and all the authors analyzed and interpreted the data. The manuscript was drafted initially by medical writers from Caudex Medical (Oxford, United Kingdom), with funding from Vifor Pharma and in line with guidance from all the authors. It was then amended substantially, critically reviewed, and edited by all the authors, who approved the final version, made the decision to submit the manuscript for publication, and vouch for the completeness and accuracy of the reported data.
Study Participants
Patients 12 to 75 years of age with active class III, IV, or V lupus nephritis who had had a clinical response to either oral mycophenolate mofetil or intravenous cyclophosphamide during the induction study 13 were randomly assigned (in a 1:1 ratio) to one of these two agents in the maintenance study. The definition of a response was based on investigator judgment but was not necessarily identical to that finally adjudicated by the clinical end-points committee. The maintenance study treatment was randomly assigned by means of a computerized, interactive voice-response system, with stratification according to induction study treatment, race, and classification of renal biopsy.
Patients were followed for 36 months, regardless of events. The vital status of patients who withdrew (with the exception of those who withdrew consent) was obtained annually for 3 years. Patients who completed the 36-month study were contacted 30 days after the last visit to obtain information about any adverse events and use of concomitant medications.
Interventions and Schedule of Assessments
At the end of the 24-week induction study, patients received oral mycophenolate mofetil (1 g, twice daily) or oral azathioprine (2 mg per kilogram of body weight per day). Patients who were unable to tolerate the target dose or whose weight was below 50 kg remained in the study if they tolerated a minimum dose of either 1 g of mycophenolate mofetil per day or 50 mg of azathioprine per day. Temporary reductions below the minimum dose or complete cessation of the drug for no more than 14 days was allowed. Any dose changes were made to both active drug and placebo. Patients could receive prednisone or its equivalent (maximum dose, 10 mg per day), with the dose reduced on the basis of the investigator's judgment.
Patients were assessed at months 0, 1, and 2 and every 3 months thereafter until month 36; at early withdrawal; or at termination due to treatment failure. Selected safety and efficacy evaluations were made at every visit, and patients were contacted by telephone monthly to obtain information about use of concomitant medications. Changes in the doses of angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, and nonsteroidal antiinflammatory agents had to be approved by the medical study monitor.
The protocol was amended in April 2009, after discussion with representatives of the European and U.S. health authorities, to make the primary end point more specific for events related to lupus nephritis and to provide a broader definition of treatment failure (the original primary end point was included as a key secondary end point). (The protocol and all amendments can be found at NEJM.org.)
Outcomes
The primary efficacy end point was the time to treatment failure, measured as the time until the first event and defined as death, end-stage renal disease, sustained doubling of the serum creatinine level, renal flare (proteinuric or nephritic), or the need for rescue therapy (glucocorticoids, plasmapheresis, intravenous immune globulin, or immunosuppressive drugs not specified in the protocol) in the event of exacerbation or deterioration of lupus nephritis. A more detailed description of the study outcomes has been reported previously 18 and is provided in the Supplementary Appendix, available at NEJM.org. Proteinuric renal flare was defined as a doubling of the urinary protein:creatinine ratio and proteinuria (≥1 g of protein per 24 hours in patients with urinary protein clearance of ≤0.5 g per 24 hours at the end of induction, and ≥2 g per 24 hours in patients with urinary protein clearance of >0.5 g per 24 hours at the end of induction). Nephritic renal flare was defined as an increase of 25% or more in the lowest serum creatinine level during the period from screening to the end of induction, plus one or more of the following findings: simultaneous doubling of urinary protein clearance, reaching a minimum of 2 g per 24 hours (or the urinary protein:creatinine ratio equivalent); new or increased hematuria (≥5 red cells per highpower field or ≥2+ on a dipstick test for blood); or the appearance of cellular casts.
Key secondary end points included the time to the event for each component of treatment failure, the time to treatment failure defined more broadly (i.e., the components of the primary end point, major extrarenal flare, or withdrawal for any reason), suspected renal flare, complete renal remission (urinary protein clearance, <500 mg per 24 hours; absence of hematuria and cellular casts; and improved or stable serum creatinine ±25% of baseline), combined renal and extrarenal remission (absence of a British Isles Lupus Assessment Group category A score [severe lupus flare] in one extrarenal system or lack of a concurrent category B score [moderate lupus flare] in three extrarenal systems 19 ), and immunologic variables (C3, C4, and anti-double-stranded DNA antibodies).
Safety assessments included clinical measurements (hematologic, serum chemical, and hormonal tests and urinalysis), adverse events, physical examination, vital signs, electrocardiographic studies, and assessment of prior and concomitant medications. As specified by the protocol, to avoid bias, the independent clinical end-points committee, whose members were unaware of the treatment assignments and adverse-event listings, reviewed all results and adjudicated each component of the primary end point and several secondary end points (i.e., suspected renal flare, major or suspected extrarenal flare, and complete extrarenal remission).
Statistical Analysis
We calculated that we would need to assign 114 patients to each group for the maintenance study to have 80% or higher power to detect differences between treatments, assuming a failure rate at 3 years of 37.5% with azathioprine and 20.0% with mycophenolate mofetil (hazard ratio with mycophenolate mofetil, 0.475), with the use of a logrank test at a two-sided significance level of 0.05.
The primary efficacy analysis was an intentionto-treat analysis that included all patients who were randomly assigned to the maintenance study and underwent at least one efficacy assessment. The safety population comprised all patients who received at least one dose of study medication and underwent at least one safety assessment. Treatment groups were compared with the use of Kaplan-Meier survival estimates for the time to treatment failure for each patient, with censoring of data for patients who withdrew before the end of the study. 20 Between-group differences in survival curves were assessed with the use of a logrank test. 21 The magnitude of the treatment effect was estimated by means of the hazard ratio obtained from an unadjusted Cox model. Hazard ratios were also estimated in subgroups stratified according to induction therapy, race, and geographic region. The overall incidence of events and the event rates per 100 person-years for both treatments are presented within subgroups. Secondary efficacy variables were analyzed by calculating hazard ratios from unadjusted Cox models. Sensitivity analyses for the primary end point were conducted, with adjustment for covariates. Testing at the significance level of 0.05 was applied to the primary efficacy analysis and to any key secondary efficacy analyses (with no adjustments for multiple comparisons). Safety variables were analyzed descriptively, with a between-group comparison of proportions of patients with adverse events.
Statistical analyses were performed with the use of SAS software, version 9.2 (SAS Institute). For analyses of changes from baseline over time (at the time of the last visit), the last-observation-carriedforward method was used. in both groups were adverse events and flares of lupus nephritis. There were no significant differences between the groups with respect to demographic or disease characteristics (Table 1) .
R e sult s
Immunosuppressive Therapies
The 
Study End Points
Mycophenolate mofetil was significantly superior to azathioprine with respect to the primary end point, time to treatment failure (hazard ratio for treatment failure, 0.44; 95% confidence interval [CI], 0.25 to 0.77; P = 0.003) (Fig. 2) . Overall observed rates of treatment failure were 16.4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the azathioprine group. The superiority of mycophenolate mofetil was consistent, regardless of induction therapy, race, and geographic region (Fig. 3) . Mycophenolate mofetil was also superior to azathioprine with respect to individual compo- 4 .5% [5 of 111], respectively; P = 0.07). The benefit of mycophenolate mofetil was maintained after adjustments were made for the serum creatinine level (P = 0.004) and the estimated glomerular filtration rate at the end of induction therapy (P = 0.004). The rates of major extrarenal flares were low: 6.9% (8 of 116 patients) in the mycophenolate mofetil group and 6.3% (7 of 111) in the azathioprine group. The time to a major extrarenal flare did not differ significantly between the two groups (P = 0.94).
During the first 3 months, the geometric mean titers of C3 and C4 in serum were lower in the azathioprine group than those in the mycophenolate mofetil group, and they remained lower throughout the study. Over time, there was a trend toward greater decreases in geometric mean titers of anti-double-stranded DNA antibodies in the patients treated with mycophenolate mofetil.
Safety and Tolerability
The incidence of adverse events during treatment was similar in the two groups: 98.3% (113 of 115 patients given mycophenolate mofetil) and 97.3% (108 of 111 patients given azathioprine, P = 0.68) ( Table 2) . For additional details, see the Supplementary Appendix. Infections were the most common adverse events in both groups, with a rate of: 79.1% (91 of 115 patients) in the mycophenolate mofetil group and 78.4% (87 of 111) in the azathioprine group. The rate of serious infections was low in both groups: 9.6% (11 of 115 patients) in the mycophenolate mofetil group and 11.7% (13 of 111) in the azathioprine group.
The proportion of patients with adverse events leading to withdrawal was higher with azathioprine (39.6% [44 of 111 patients]) than with mycophenolate mofetil (25.2% [29 of 115], P = 0.02). Fewer patients in the mycophenolate mofetil group than in the azathioprine group had at least one serious adverse event, although the difference was not significant (23.5% [27 of 115 patients] vs. 33.3% [37 of 111], P = 0.11). During the study, one death occurred in the azathioprine group and was due to a traffic accident. One case of cancer (uterine carcinoma in situ) was diagnosed in the azathioprine group.
Discussion
There are few data concerning maintenance therapy for lupus nephritis. 8, 11 A suboptimal response to treatment in patients with class III, IV, or V lupus nephritis increases the risk of end-stage renal disease. 23 The early National Institutes of Health (NIH) regimen of intravenous cyclophosphamide became the standard of care in many countries but was challenged by a long-term maintenance trial showing that oral mycophenolate mofetil and oral azathioprine were each superior to the standard 2-year NIH cyclophosphamide regimen. 11 In an open-label study of maintenance therapy in 105 patients with lupus nephritis, Houssiau et al. 8 reported no significant difference in relapse rates between patients who were randomly assigned to receive azathioprine and those assigned to receive mycophenolate mofetil. Renal flares were observed in 10 of 53 patients given mycophenolate mofetil (18.9%), as compared with 13 of 52 patients given azathioprine (25.0%).
In our study, mycophenolate mofetil was superior to azathioprine in maintaining the renal response and in preventing relapse in patients with active lupus nephritis who had had a response to induction therapy with either mycophenolate mofetil or cyclophosphamide. There were few nephritic flares, an expected finding, since the majority of patients entered the induction study with ongoing proteinuria rather than clinical nephritis. Even when broader end-point criteria were applied, mycophenolate mofetil proved superior to azathioprine. The results for other key secondary end points also confirmed the superiority of mycophenolate mofetil over azathioprine -findings that were consistent regardless of the induction therapy received, race, and geographic region. Rates of complete remission at the end of induction therapy were low (8.6% with mycophenolate mofetil and 8.1% with cyclophosphamide). 13 Although the aim of the study was to prevent relapse, patients in both treatment groups continued to have improvement, with complete remission eventually achieved in 62.1% of patients in the mycophenolate mofetil group (72 of 116) and in 59.5% of those in the azathioprine group (66 of 111). This finding suggests that the distinction between induction therapy and maintenance therapy in patients with lupus nephritis may be an artificial one.
Little extrarenal lupus activity was observed in either group at the start of maintenance therapy or at the end of the study, which probably reflects the requirement of a clinical response for entry into the maintenance study. Adverse events were common in both groups and were consistent with previous findings. 8, 11, 13 One death occurred in the azathioprine group and the frequency of serious infections was low in both groups. Azathioprine was associated with adverse hematologic events (a finding that is consistent with its known safety profile), and serious adverse events and withdrawals from the study were also more common in this treatment group.
This study was not powered to draw conclusions about subsets of patients. Few repeat renal biopsies were performed during the study, which also limits the ability to draw conclusions about possible treatment benefits with respect to active disease or chronic renal damage.
Although our trial included more patients and was substantially longer than many of the controlled trials involving patients with lupus nephritis, [6] [7] [8] 11, 24 potential outcomes that might appear more frequently after 5 to 20 years (e.g., cardiovascular complications and end-stage renal disease) cannot be determined, since no further follow-up study is planned. The length of time that treatment with mycophenolate mofetil needs to be continued is unknown; hence, improved biomarkers of response are needed to distinguish disease remission from remission that occurs while the patient is receiving treatment. Patients who had a clinical response after 6 months of induction therapy were included in this maintenance study. Those patients whose disease was more difficult to treat, therefore, may have been excluded. Since many black patients did not meet the clinical response criteria, few were included in the maintenance trial. Most patients reached their target dose and remained in the maintenance study for the full 36 months. The study was adequately powered to assess the primary composite outcome, which was achieved, with results consistent across the treatment groups.
We conclude that mycophenolate mofetil is superior to azathioprine in maintaining the renal response to treatment and in preventing relapse in patients with active lupus nephritis who have had a clinical response to induction therapy with either mycophenolate mofetil or intravenous cyclophosphamide. Only adverse events that occurred during treatment are listed; these include any nonserious adverse event that occurred between the date of the first dose and the date of the last visit plus 14 days and any serious adverse event that occurred after the date of the first dose. Multiple occurrences of the same adverse event in one person were counted only once. † One patient in this group was randomly assigned to treatment in error and did not receive the study drug. ‡ This category includes all patients who had at least one adverse event.
